SPERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.46 USD | +2.10% |
|
+4.29% | -0.68% |
| 03-13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
| 03-13 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Chart calendar Spero Therapeutics, Inc.
f668ebefe83139ddff8b07b7fbcc0d86.H1qQ8SQ_wqTswXr_u3kY6ugTA8fcL2-AphBos6P6h4E.TGzAsFcGqteq8w2U-RctjIN_NbKLZw63_0kbwdGv5c16NNXCQGqT6dv5HQ~6f2c7fd687d6d4750a2524942450f49f
Upcoming events on Spero Therapeutics, Inc.
Past events on Spero Therapeutics, Inc.
| 13/03/2024 20:30 | Q4 2023 Earnings Call |
| 13/03/2024 20:01 | Q4 2023 Earnings Release |
| 04/03/2024 14:50 | TD Cowen Health Care Conference |
| 28/11/2023 12:55 | Evercore ISI HealthCONx Conference |
| 13/11/2023 21:30 | Q3 2023 Earnings Call |
| 13/11/2023 21:05 | Q3 2023 Earnings Release |
| 08/11/2023 13:00 | Truist Securities Healthcare Conference |
| 05/10/2023 14:00 | Annual General Meeting |
| 26/09/2023 21:20 | Cantor Global Healthcare Conference - Fireside Chat |
| 12/09/2023 16:30 | H.C. Wainwright Global Investment Conference |
| 10/08/2023 21:30 | Q2 2023 Earnings Call |
| 10/08/2023 21:05 | Q2 2023 Earnings Release |
| 11/05/2023 21:30 | Q1 2023 Earnings Call |
| 11/05/2023 21:05 | Q1 2023 Earnings Release |
| 02/05/2023 15:30 | H.C. Wainwright BioConnect Investor Conference |
| 14/04/2023 | European Congress of Clinical Microbiology and Infectious Diseases - Poster Session: 3b #P0245 |
| 14/04/2023 | European Congress of Clinical Microbiology and Infectious Diseases - Poster Session: 3b #P0151 |
| 30/03/2023 21:30 | Q4 2022 Earnings Call |
| 30/03/2023 21:05 | Q4 2022 Earnings Release |
| 14/03/2023 20:00 | Oppenheimer Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 18,1 18,2 -0.41% | 9,33 11,1 -15.73% | 18,3 19,5 -6.24% | 53,5 29,0 84.79% | 104 48,9 112.29% | 48,2 |
|
EBITDA Million USD | Released Forecast Spread | -62,5 -59,4 -5.12% | -78,4 -77,0 -1.76% | -87,3 -84,0 -3.96% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -63,2 -58,3 -8.48% | -79,1 -79,7 0.72% | -88,0 -83,9 -4.86% | -42,2 -61,6 31.47% | 21,5 -34,5 162.35% | -54,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -60,9 -55,5 -9.73% | -78,3 -77,8 -0.64% | -89,8 -83,2 -7.83% | -46,4 -56,9 18.44% | 25,4 -25,9 197.95% | -51,6 |
|
Net income Million USD | Released Forecast Spread | -60,9 -56,8 -7.17% | -78,8 -78,9 0.1% | -89,8 -84,3 -6.45% | -46,4 -70,4 34.08% | 22,8 -33,7 167.75% | -53,7 |
|
EPS USD | Released Forecast Spread | -3,35 -3,13 -6.88% | -3,52 -3,58 1.63% | -2,91 -2,89 -0.81% | -1,23 -2,12 41.98% | 0,43 -0,69 162.55% | -0,94 |
| Announcement Date | 16/03/20 | 11/03/21 | 31/03/22 | 30/03/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,74 4,95 -44.57% | 2,07 1,93 7.48% | 1,99 1,43 39.05% | 2,01 5,42 -62.97% | 47,4 22,9 107.47% | 2,07 1,27 63.34% | 2,72 1,08 150.71% | 25,5 15,0 70.2% | 73,5 18,6 294.58% | 21,5 | 0,60 | 21,5 | 4,60 | 13,0 |
|
EBIT Million USD | Released Forecast Spread | -27,5 -23,9 -15.3% | -30,2 -29,6 -2.22% | -14,2 -29,0 50.98% | -12,0 -9,98 -20.06% | 25,9 6,53 296.8% | -14,2 -17,2 17.44% | -12,9 -18,4 29.88% | 3,37 -1,20 381% | 50,5 -6,00 942.22% | -2,70 | -24,5 | -4,87 | -22,8 | -6,30 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -29,2 -22,5 -30.16% | -32,8 -31,3 -4.77% | -28,7 -30,7 6.71% | -11,7 -11,3 -3.41% | 26,8 16,3 64.44% | -13,3 -19,2 30.89% | -11,9 -19,5 38.82% | -0,99 0,43 -333.88% | 51,6 3,50 1373.69% | -3,23 | -23,3 | -5,38 | -19,7 | |
|
Net income Million USD | Released Forecast Spread | -29,2 -24,2 -20.78% | -32,8 -30,3 -8.19% | -28,7 -30,4 5.54% | -11,7 -10,3 -13.79% | 26,8 2,79 860.57% | -13,3 -17,2 22.86% | -11,9 -18,2 34.36% | -3,21 -1,82 -76.42% | 51,2 -5,27 1072% | -2,38 | -24,2 | -4,62 | -22,6 | -6,30 |
|
EPS USD | Released Forecast Spread | -0,92 -0,75 -23.08% | -1,01 -0,93 -8.6% | -0,87 -0,93 6.12% | -0,33 -0,30 -8.79% | 0,93 0,04 2046.32% | -0,25 -0,33 25% | -0,23 -0,34 33.01% | -0,06 -0,03 -100% | 0,96 -0,10 1060% | -0,04 | -0,44 | -0,08 | -0,38 | -0,10 |
| Announcement Date | 31/03/22 | 16/05/22 | 10/08/22 | 14/11/22 | 30/03/23 | 11/05/23 | 10/08/23 | 13/11/23 | 13/03/24 | - | - | - | - | - |
More events
Past sector events for Spero Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SPRO Stock
- Calendar Spero Therapeutics, Inc.
